Myopia - from genes and environment to cellular responses and treatment

MSCA (Marie Skłodowska-Curie)HORIZON-TMA-MSCA-DNID: 101119501
EC Contribution
€27,477
Consortium Size
12 orgs
Start Year
2023
Summary

In modern industrial societies, myopia has become an important ocular health problem of young people, due to its increased incidence and associated complications, which pose a significant risk of blindness already in the middle life span. Current treatment options have limited effects with a maximum reduction of axial elongation by about 0.4 mm over several years, equivalent to a reduction in myopia by only about 1 D. Eye growth is controlled by an interplay of different biochemical pathways, one inhibitory (stimulated by image plane in front of the retina) and one stimulatory (image plane behind the retina). A novel future strategy would be to activate the inhibitory pathways rather than inhibit the growth stimulating pathways (standard target in most studies). At present, interventions to activate growth inhibition are poorly studied. The influence of environmental factors (spectral composition of ambient light) and gene-environment interactions (specific gene variants and their interaction with key lifestyle exposures) on eye growth and refractive development will be investigated. New pharmacological targets will be identified and tested, and biomarkers established to detect the onset of myopia at an earlier stage. It will be studied how choroidal hypoxia relates to choroidal thinning and axial eye growth and how it interacts with the metabolic processes in the retina and sclera. New measurement techniques will be developed that implement artificial intelligence algorithms to improve diagnostics in myopia studies, especially in the periphery of the visual field. The proposed intersectorial and interdisciplinary ""MyoTreat"" project (including anatomy, physiology, pharmacology, optics, and genetics) will train PhD students in myopia research and generate and disseminate novel research results. The ultimate scientific goal is to identify new strategies for myopia therapy through hypothesis-driven translational research in various animal models as well as in humans.""

Consortium (12)

Project Results (6)

Source: CORDIS, the EU research results database.

Publications (6)
<i>EGFLAM</i> Pathogenic Variants and Congenital Stationary Night Blindness
JAMA Ophthalmology· 2025DOI
Sanja Boranijasevic, Vasily Smirnov, Julien Navarro, Martha Tjon-Fo-Sang, Christel Condroyer, Lonneke Haer-Wigman, Aline Antonio, Claire-Marie Dhaenens, Virginie J. M. Verhoeven, José-Alain Sahel, L.
Advances in the genetics of refractive errors: Contributions from the <scp>CREAM</scp> consortium
Acta Ophthalmologica· 2025DOI
Sze Wai Rosa Li, Xi He, Louise Terry, Virginie J. M. Verhoeven, Samantha Sze‐Yee Lee, Gareth Lingham, Jeremy A. Guggenheim, David A. Mackey, Seang‐Mei Saw, Caroline C. W. Klaver, Chi Pui Pang, nul
Mechanism of optical treatments for myopia: Are lenslets joining the DOTs?
Ophthalmic and Physiological Optics· 2025DOI
Jeremy A. Guggenheim, Louise Terry
Mendelian Randomization Studies of Myopia: Choosing the Right Summary Statistics
Investigative Ophthalmology & Visual Science· 2025DOI
Thu Nga Nguyen, Louise Terry, Jeremy A. Guggenheim
Myopia is predominantly genetic or predominantly environmental?
Ophthalmic and Physiological Optics· 2025DOI
Virginie J. M. Verhoeven, Ian G. Morgan, Jeremy A. Guggenheim
The structure and function of the human choroid
Annals of Anatomy - Anatomischer Anzeiger· 2024DOI
Weina Zhang, Alexandra Kaser-Eichberger, Wanlin Fan, Christian Platzl, Falk Schrödl, Ludwig M. Heindl